AstraZeneca: Voydeya Recommended For Approval In The EU By CHMP - Quick Facts

(RTTNews) - AstraZeneca PLC (AZN.L, AZN) announced Voydeya has been recommended for marketing authorisation in the European Union as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria who have residual haemolytic a https://www.nasdaq.com/articles/astrazeneca:-voydeya-recommended-for-approval-in-the-eu-by-chmp-quick-facts